Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CRB-401 A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Next Previous
Trial Profile

CRB-401 A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 24 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Idecabtagene vicleucel (Primary) ; Dexamethasone; Lenalidomide; Nivolumab; Pomalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions; First in man
  • Sponsors Celgene Corporation

Most Recent Events

  • 20 Jan 2023 Status changed from active, no longer recruiting to completed.
  • 13 Dec 2022 Results (n=4) evaluating nivolumab (anti-PD1)- based triplet therapy patients who were salvaged at the time of clinical relapse to first or second Idecabtagene Vicleucel infusion, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
  • 20 Jan 2022 According to a Bristol-Myers Squibb media release, based on results from this and BB2121-MM-001 trials, the Japan's Ministry of Health, Labour and Welfare has approved Abecma (idecabtagene vicleucel), for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, and have either experienced disease progression or relapse on the last therapy.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top